Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Losartan Reduces the Increased Participation of Cyclooxygenase-2-Derived Products in Vascular Responses of Hypertensive Rats

Yolanda Álvarez, José V. Pérez-Girón, Raquel Hernanz, Ana M. Briones, Ana García-Redondo, Amada Beltrán, María J. Alonso and Mercedes Salaices
Journal of Pharmacology and Experimental Therapeutics April 2007, 321 (1) 381-388; DOI: https://doi.org/10.1124/jpet.106.115287
Yolanda Álvarez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José V. Pérez-Girón
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Hernanz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana M. Briones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana García-Redondo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amada Beltrán
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María J. Alonso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercedes Salaices
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

This study analyzes the role of angiotensin II (Ang II), via AT1 receptors, in the involvement of cyclooxygenase (COX)-2-derived prostanoids in phenylephrine responses in normotensive rats (Wistar Kyoto; WKY) and spontaneously hypertensive rats (SHR). Aorta from rats untreated or treated for 12 weeks with losartan (15 mg/kg · day) or hydralazine plus hydrochlorothiazide (44 and 9.4 mg/kg · day, respectively) and vascular smooth muscle cells (VSMC) from SHR were used. Vascular reactivity was analyzed by isometric recording; COX-2 expression by Western blot and reverse transcription-polymerase chain reaction; prostaglandin (PG)I2, PGF2α, 8-isoprostane, and total antioxidant status (TAS) by commercial kits; superoxide anion (Math) by lucigenin chemiluminescence; and plasmatic malondialdehyde (MDA) by thiobarbituric acid assay. The COX-2 inhibitor N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methane sulfonamide (NS-398) at 1 μM reduced phenylephrine responses more in SHR than in WKY rats. COX-2 protein and mRNA expressions, PGF2α, PGI2, 8-isoprostane, and Math production, and MDA levels were higher in SHR, but TAS was similar in both strains. Losartan, but not hydralazine-hydrochlorothiazide treatment, reduced COX-2 expression and the effect of NS-398 on phenylephrine responses in SHR. Losartan also increased TAS and reduced PGF2α, PGI2, 8-isoprostane, and Math production and MDA levels in SHR. Ang II (0.1 μM) induced COX-2 expression in VSMC from SHR that was reduced by 30 μM apocynin and 100 μM allopurinol, NADPH oxidase, and xanthine oxidase inhibitors, respectively. In conclusion, AT1 receptor activation by Ang II could be involved in the increased participation of COX-2-derived contractile prostanoids in vasoconstriction to phenylephrine with hypertension, probably through COX-2 expression regulation. The increased oxidative stress seems to be one of the mechanisms involved.

Footnotes

  • This study was supported by Ministerio de Educacíon y Ciencia Grants (SAF2003-00633 and SAF2006-02376, Fondo de Investigaciones Sanitarias Grant (PIOY1917), and Red Temática de Investigación Cardiovascular Grant (RD06/0014/0011). Part of this work was presented at the 15th European Meeting on Hypertension; 2005 17–21 Jun; Milan, Italy. European Society of Hypertension, Milan, Italy.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.115287.

  • ABBREVIATIONS: COX, cyclooxygenase; Ang II, angiotensin II; ROS, reactive oxygen species; VSMC, vascular smooth muscle cell(s); SHR, spontaneously hypertensive rat(s); WKY, Wistar Kyoto; HH, hydralazine-hydrochlorothiazide; MDA, malondialdehyde; TAS, total antioxidant status; NS-398, N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methane sulfonamide; RT-PCR, reverse transcription-polymerase chain reaction; PG, prostaglandin; ANOVA, analysis of variance; SQ 29,548, [1S-[1α,2β(5Z)3β,4α]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxobicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid.

    • Received October 10, 2006.
    • Accepted January 19, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Losartan Reduces the Increased Participation of Cyclooxygenase-2-Derived Products in Vascular Responses of Hypertensive Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Losartan Reduces the Increased Participation of Cyclooxygenase-2-Derived Products in Vascular Responses of Hypertensive Rats

Yolanda Álvarez, José V. Pérez-Girón, Raquel Hernanz, Ana M. Briones, Ana García-Redondo, Amada Beltrán, María J. Alonso and Mercedes Salaices
Journal of Pharmacology and Experimental Therapeutics April 1, 2007, 321 (1) 381-388; DOI: https://doi.org/10.1124/jpet.106.115287

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Losartan Reduces the Increased Participation of Cyclooxygenase-2-Derived Products in Vascular Responses of Hypertensive Rats

Yolanda Álvarez, José V. Pérez-Girón, Raquel Hernanz, Ana M. Briones, Ana García-Redondo, Amada Beltrán, María J. Alonso and Mercedes Salaices
Journal of Pharmacology and Experimental Therapeutics April 1, 2007, 321 (1) 381-388; DOI: https://doi.org/10.1124/jpet.106.115287
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Optimized S-nitrosohemoglobin synthesis in red blood cells
  • High-Salt Diet Upregulates CaSR Expression and Signaling
  • L-Arginine improves post-infarction physical function
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics